CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS) von Garcia-Manero, G, Savona, M.R, Gore, S.D, Scott, B.L, Cogle, C.R, Boyd, T, Conkling, P, Hetzer, J, Dong, Q, Kumar, K, Ukrainskyj, S.M, Skikne, B.S

Volltext

99 CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS)-DEFINED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) von Garcia-Manero, G, Savona, M.R, Gore, S.D, Cogle, C.R, Conkling, P, Hetzer, J, Dong, Q, Ukrainskyj, S.M, Skikne, B.S

Volltext

60 EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLE... von Savona, M.R, Kolibaba, K, Conkling, P, Kingsley, E.C, Becerra, C, Morris, J.C, Rifkin, R.M, Laille, E, Kellerman, A, Ukrainskyj, S.M, Dong, Q, Skikne, B.S

Volltext

337TiP An open-label, phase Ib/II study to evaluate the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced triple-negative breast cancer von Tripathy, D., Ukrainskyj, S.M., Yang, Z., Kania, M., Schelman, W., Hamilton, E.

Volltext

25 - CC-486 (Oral Azacitidine) Induces Responses in Patients with Hematological Malignancies Who had Failed Prior Treatment with Injectable Hypomethylating Agents (HMAS) von Garcia-Manero, G., Savona, M.R., Gore, S.D., Scott, B.L., Cogle, C.R., Boyd, T., Conkling, P., Hetzer, J., Dong, Q., Kumar, K., Ukrainskyj, S.M., Skikne, B.S.

Volltext